GlaxoSmithKline PLC ADR (GSK) Stock Price

GSK plc generates revenue through its Commercial Operations segment by selling specialty medicines such as oncology, respiratory/immunology, and inflammation treatments for conditions including ovarian cancer, endometrial cancer, lupus, and respiratory eosinophil-driven diseases. The company also sells vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, and Human Papilloma Virus, among others, to healthcare providers and governments globally. General medicines for asthma, COPD, bacterial infections, and skin conditions are distributed through pharmaceutical channels to patients and healthcare systems. The Total R&D segment focuses on developing oral small molecule therapies for oncology and inflammatory diseases, which are later commercialized under the Commercial Operations segment. GSK's specialty medicines target healthcare providers treating complex conditions, while vaccines are purchased by governments and healthcare systems for public health programs. General medicines are sold to pharmacies and hospitals for patient use. The company collaborates on research and development with partners to advance treatments for unmet medical needs in oncology and inflammatory diseases, which are then marketed under GSK's brand portfolio. The Commercial Operations segment drives revenue from all product lines, including vaccines, specialty medicines, and general medicines, sold to healthcare providers, governments, and consumers. R&D investments in oral small molecule therapies for oncology and inflammatory diseases are integral to the company's pipeline, with commercialization handled through established pharmaceutical distribution networks. GSK's product portfolio spans multiple therapeutic areas, ensuring steady demand across diverse medical segments.